^
Association details:
| Biomarker: | ATM L804fs*4 |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | everolimus (mTOR inhibitor) + Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Excerpt:
...the second patient was a 35-year-old man with sporadic medullary thyroid carcinoma and a RET M918T mutation as well as ATM L804fs*4 and ATM S978fs*12 alterations. Additional tumor evaluation with an IHC panel also showed strong positivity of phospho-AKT. The patient was initially treated with single-agent vandetanib with prolonged stable disease; however, the addition of everolimus led to significant tumor shrinkage.
DOI:
10.1158/1078-0432.CCR-16-1679
Trial ID:
